Hennadii V. Khmelnytskyi
Research Subjects
Hennadii V. Khmelnytskyi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Iryna V. Kruchok
Department of Neuroradiology and Radioneurosurgery, Romodanov Neurosurgery Institute, Kyiv
4 shared publications - Oksana V. Zemskova
State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine
4 shared publications - Oleksandr Yakovych Glavatskyi
Державна установа «Інститут нейрохірургії ім. акад. А. П. Ромоданова НАМН України», Україна, 04050, м. Київ, вул. П. Майбороди, 32
4 shared publications - Andrey B. Gryazov
State Institution «Romodanov Neurosurgery Institute National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine
3 shared publications - Olga Yuriivna Chuvashova
State Institution «Romodanov Neurosurgery Institute National Academy of Medical Sciences of Ukraine», Kyiv, Ukraine
3 shared publications - Volodymyr A. Stuley
National Technical University of Ukraine «Igor Sikorsky Kyiv Polytechnic Institute», Institute for Applied Systems Analysis of the Ministry of Education and Science of Ukraine, Kyiv, Ukraine
3 shared publications
Latest Publications
- Open Access
- 31 March 2025
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 33 (1) , 41-56
Adjuvant antiangiogenic targeted therapy in the radiosurgical treatment of recurrent cerebral metastases
Background. Stereotactic radiosurgery (SRS) is a standard treatment method for patients with primary brain metastases regardless of their tumor nosology. At the same time, there are not any standard treatment methods for recurrent brain metastases, which have a significantly worse prognosis. Our own experience and literature data indicate that the combination of radiation therapy and antiangiogenic targeted drug bevacizumab (BEV) improves treatment results in both primary malignant and metastatic tumors of the brain. Purpose – to assess the efficacy and safety of BEV in repeated radiosurgery of recurrent brain metastases after high-dose radiation therapy. Materials and methods. The prospective unicentral nonrandomized study was conducted in the State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» (2017–2024). It involved a sample of 16 patients with recurrent brain metastases of the most common tumor nosologies to the brain. The patients previously received high-dose radiosurgical treatment for primary brain metastases. In cases of metastatic recurrence, both single-fraction and multi-fraction radiosurgery were used. They were performed using the Trilogy linear accelerator with bremsstrahlung energy of 6 MeV. The dose ranged from 15 to 22.5 Gy. BEV was used as an adjuvant drug in all patients after radiation therapy to decrease symptoms of radiotoxicity and worsening of quality of life caused by it. The patients received from 2 to 18 courses of BEV at a dose of 10 mg/kg of weight with an interval of 3 weeks. We conducted an overall survival analysis of patients who received BEV after radiosurgical treatment of recurrent brain metastases. Results. The time of development of recurrent brain metastases after the first high-dose SRS ranged from 7 to 18 months with a median survival of 12 months. The patients were receiving radiosurgical treatment for recurrent brain metastases in combination with BEV from May 2019 to December 2023. One-year overall survival was 68.7% with a median of 21 months, which surpassed the median survival after the first radiosurgery by 9 months. The neurological deficit fully regressed in 9 patients (56.3%). In other patients, significant neurological improvement was achieved. At the time of analysis, 8 patients were still followed up. The use of BEV in patients with brain metastases after radiosurgical treatment demonstrated an acceptable toxicity profile. According to CTCAE v5.0, no cases of grade 3–5 adverse events were registered. MRI imaging over the course of time showed a positive response in terms of achieving local control in 87.6% of cases. Conclusions. The use of BEV allows toxic symptoms of repeated radiosurgical treatment to be minimized and the duration and quality of life of patients to be improved. The clinical effect was supported by a clear radiological response according to the MRI imaging data.
- 31 March 2025
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 33 (1) , 41-56
Open AccessAdjuvant antiangiogenic targeted therapy in the radiosurgical treatment of recurrent cerebral metastases
Background. Stereotactic radiosurgery (SRS) is a standard treatment method for patients with primary brain metastases regardless of their tumor nosology. At the same time, there are not any standard treatment methods for recurrent brain metastases, which have a significantly worse prognosis. Our own experience and literature data indicate that the combination of radiation therapy and antiangiogenic targeted drug bevacizumab (BEV) improves treatment results in both primary malignant and metastatic tumors of the brain. Purpose – to assess the efficacy and safety of BEV in repeated radiosurgery of recurrent brain metastases after high-dose radiation therapy. Materials and methods. The prospective unicentral nonrandomized study was conducted in the State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» (2017–2024). It involved a sample of 16 patients with recurrent brain metastases of the most common tumor nosologies to the brain. The patients previously received high-dose radiosurgical treatment for primary brain metastases. In cases of metastatic recurrence, both single-fraction and multi-fraction radiosurgery were used. They were performed using the Trilogy linear accelerator with bremsstrahlung energy of 6 MeV. The dose ranged from 15 to 22.5 Gy. BEV was used as an adjuvant drug in all patients after radiation therapy to decrease symptoms of radiotoxicity and worsening of quality of life caused by it. The patients received from 2 to 18 courses of BEV at a dose of 10 mg/kg of weight with an interval of 3 weeks. We conducted an overall survival analysis of patients who received BEV after radiosurgical treatment of recurrent brain metastases. Results. The time of development of recurrent brain metastases after the first high-dose SRS ranged from 7 to 18 months with a median survival of 12 months. The patients were receiving radiosurgical treatment for recurrent brain metastases in combination with BEV from May 2019 to December 2023. One-year overall survival was 68.7% with a median of 21 months, which surpassed the median survival after the first radiosurgery by 9 months. The neurological deficit fully regressed in 9 patients (56.3%). In other patients, significant neurological improvement was achieved. At the time of analysis, 8 patients were still followed up. The use of BEV in patients with brain metastases after radiosurgical treatment demonstrated an acceptable toxicity profile. According to CTCAE v5.0, no cases of grade 3–5 adverse events were registered. MRI imaging over the course of time showed a positive response in terms of achieving local control in 87.6% of cases. Conclusions. The use of BEV allows toxic symptoms of repeated radiosurgical treatment to be minimized and the duration and quality of life of patients to be improved. The clinical effect was supported by a clear radiological response according to the MRI imaging data.
- Open Access
- 2 July 2024
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 32 (2)
The analysis of quality of life of patients with glioblastoma after adjuvant radiation therapy
Background. Optimizing approaches to the treatment of patients with glioblastoma (GB) is an urgent task partly owing to the wider implementation of hypofractionated radiation therapy (HRT) regimens. At the same time, increasing survival without maintaining the patient’s quality of life (QoL) cannot be considered successful treatment. Purpose – to analyze QoL of patients with GB after adjuvant radiation treatment in the groups of standard and hypofractionated radiation regimens. Materials and methods. 159 patients with verified GB, who had undergone surgery in State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» over the period from 2014 to 2020, were divided into two groups according to the regimen of RT: SRT group (n = 49) – standard regimen (total dose 60.0 Gy in 30 fractions over 6 weeks); HRT group (n = 110) – hypofractionated regimen (total dose 52.5 Gy in 15 fractions over 3 weeks). The patients were surveyed about QoL three times during their follow-up (3, 6 and 12 months after RT) according to the Global Health Status Scale (GHSS), domains of insomnia and fatigue of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30 version 3.0). Statistical analysis was performed separately for each group (SRT and HRT; intragroup analysis), as well as between SRT and HRT groups as comparison of independent groups with a different number of follow-up examinations for each period of the follow-up (intergroup analysis). Results. The H0 hypothesis about the absence of statistically significant difference between the results of three subsequent surveys according to the GHSS, domains of insomnia and fatigue in both SRT (p = 0.00003; p = 0.00002; p = 0.00002, respectively) and HRT (p = 0.00000; p = 0.00001; p = 0.00001, respectively) groups in the intragroup analysis according to the Friedman test was rejected. The pairwise comparison of the results of the second and the first survey (6 vs. 3 months) according to the Wilcoxon test showed a statistically significant decrease in QoL in the domain of insomnia (р = 0.000733) in SRT group and in the domain of fatigue (р = 0.016813) in HRT group. When comparing the results of the third and the second survey (12 vs. 6 months), the H0 hypothesis for all the studied parameters of QoL (GHS, insomnia, and fatigue) was rejected in both SRT and HRT groups (p ≤ 0.017 with the Bonferroni correction). When comparing the results of the third and the first survey (12 vs. 3 months), a statistically significant decrease in QoL in all studied parameters of QoL was observed: GHSS (р = 0.000078); fatigue (р = 0.000294); insomnia (р = 0.000318). The comparison of the results of these surveys in SRT group showed a statistically significant decrease of QoL in GHSS (р = 0.004650) and fatigue (p = 0.017938), with the level of statistical significance getting closer to the set critical value considering the Bonferroni correction. The intergroup analysis according to the Mann-Whitney U test showed a statistically significant advantage of HRT over SRT in all studied parameters of QoL in three subsequent surveys (p < 0.05). The ρ-test confirmed these data: HRT group patients had better parameters of QoL than SRT group patients over the whole period of the follow-up. Conclusions. The analysis of QoL according to the results of three subsequent surveys 3, 6, and 12 months after RT according to the GHSS, domains of insomnia and fatigue of the EORTC QLQ-C30 demonstrated a decrease in QoL of patients in both SRT and HRT groups. At the same time, a statistically significant advantage of HRT group over SRT group in all studied parameters of SRT was observed when the results of three subsequent surveys were compared. The proposed regimen of HRT for patients with primarily diagnosed GB may be considered an acceptable alternative to SRT in view of impact on QoL.
- 2 July 2024
- Published by Institute for Medical Radiology and Oncology of NAMS of Ukraine in Український радіологічний та онкологічний журнал
- Vol. 32 (2)
Open AccessThe analysis of quality of life of patients with glioblastoma after adjuvant radiation therapy
Background. Optimizing approaches to the treatment of patients with glioblastoma (GB) is an urgent task partly owing to the wider implementation of hypofractionated radiation therapy (HRT) regimens. At the same time, increasing survival without maintaining the patient’s quality of life (QoL) cannot be considered successful treatment. Purpose – to analyze QoL of patients with GB after adjuvant radiation treatment in the groups of standard and hypofractionated radiation regimens. Materials and methods. 159 patients with verified GB, who had undergone surgery in State Institution «Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine» over the period from 2014 to 2020, were divided into two groups according to the regimen of RT: SRT group (n = 49) – standard regimen (total dose 60.0 Gy in 30 fractions over 6 weeks); HRT group (n = 110) – hypofractionated regimen (total dose 52.5 Gy in 15 fractions over 3 weeks). The patients were surveyed about QoL three times during their follow-up (3, 6 and 12 months after RT) according to the Global Health Status Scale (GHSS), domains of insomnia and fatigue of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30 version 3.0). Statistical analysis was performed separately for each group (SRT and HRT; intragroup analysis), as well as between SRT and HRT groups as comparison of independent groups with a different number of follow-up examinations for each period of the follow-up (intergroup analysis). Results. The H0 hypothesis about the absence of statistically significant difference between the results of three subsequent surveys according to the GHSS, domains of insomnia and fatigue in both SRT (p = 0.00003; p = 0.00002; p = 0.00002, respectively) and HRT (p = 0.00000; p = 0.00001; p = 0.00001, respectively) groups in the intragroup analysis according to the Friedman test was rejected. The pairwise comparison of the results of the second and the first survey (6 vs. 3 months) according to the Wilcoxon test showed a statistically significant decrease in QoL in the domain of insomnia (р = 0.000733) in SRT group and in the domain of fatigue (р = 0.016813) in HRT group. When comparing the results of the third and the second survey (12 vs. 6 months), the H0 hypothesis for all the studied parameters of QoL (GHS, insomnia, and fatigue) was rejected in both SRT and HRT groups (p ≤ 0.017 with the Bonferroni correction). When comparing the results of the third and the first survey (12 vs. 3 months), a statistically significant decrease in QoL in all studied parameters of QoL was observed: GHSS (р = 0.000078); fatigue (р = 0.000294); insomnia (р = 0.000318). The comparison of the results of these surveys in SRT group showed a statistically significant decrease of QoL in GHSS (р = 0.004650) and fatigue (p = 0.017938), with the level of statistical significance getting closer to the set critical value considering the Bonferroni correction. The intergroup analysis according to the Mann-Whitney U test showed a statistically significant advantage of HRT over SRT in all studied parameters of QoL in three subsequent surveys (p < 0.05). The ρ-test confirmed these data: HRT group patients had better parameters of QoL than SRT group patients over the whole period of the follow-up. Conclusions. The analysis of QoL according to the results of three subsequent surveys 3, 6, and 12 months after RT according to the GHSS, domains of insomnia and fatigue of the EORTC QLQ-C30 demonstrated a decrease in QoL of patients in both SRT and HRT groups. At the same time, a statistically significant advantage of HRT group over SRT group in all studied parameters of SRT was observed when the results of three subsequent surveys were compared. The proposed regimen of HRT for patients with primarily diagnosed GB may be considered an acceptable alternative to SRT in view of impact on QoL.
- Open Access
- 27 March 2023
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 29 (1) , 38-47
Hypofractionated radiotherapy of patients with glioblastoma: the first experience in Ukraine and prospects view
Objective: To assess the survival of patients (pts) with newly diagnosed glioblastoma (GBM) in groups with hypofractionated regime radiotherapy, standard fractionationated regime radiotherapy and whole brain irradiation. Materials and methods: A retrospective non-randomized single-center study of 205 pts with GBM grade 4 according to the WHO classification treated in Romodanov Neurosurgery Institute named after Acad. A.P. Romodanov National Academy of Medical Science of Ukraine (2014–2020). The mean age of pts 53.8 years (95% CI 52.1 - 55.5); there were 114 men (55.6%) and 91 women (44.4%). According to the regimen radiotherapy (RT), pts were divided into 3 groups: 49 (23.9%) pts (standard RT: 2.0 Gy per fraction in 30 fractions, total dose 60.0 Gy) – group "sRT", 110 (53.7%) pts (hypofractionated RT: 3.5 Gy per fraction in 15 fractions, total dose 52, 5 Gy) - group "hRT", 46 (22.4%) pts – group "WBRT" (whole brain radiation). Differences in progression-free survival (PFS) and overall survival (OS) between the three groups were analyzed using Kaplan–Meier survival curve, log-rank test and Pearson Chi-square test. Results: The median OS is 15,0 (95% CI 14,1 – 17,1), 16,5 (95% CI 14,1 – 18,8) and 8,7 (95% CІ 7,5 – 9,5) months for sRT, hRT and WBRT, respectively. There is a significant difference in OS for sRT and hRT compared to WBRT (p=0.00000), without difference in OS between sRT and hRT (p=0.06757). The median PFS in sRT and hRT does not differ significantly: sRT – 9.0 (95% CI 9.0 - 10.0) months; hRT – 9.0 (95% CI 8.0 - 10.0) months. The median OS for WBRT is 5.1 (95% CI 4.0 - 6.0) months. There is a significant difference in PFS for sRT and hRT compared to the WBRT (p=0.00000), without difference in PFS between sRT and hRT (p=0.43374). The risk of death for WBRT compared to sRT is 2.5 times higher (HR 2.5 [95% CI, 1.45 - 4.46)) and 3.5 times higher compared to the hRT group (HR 3.5 [95% CI, 2.09-5.88)). The risk of progression for WBRT is 2.8 times higher (HR 2.78 [95% CI, 1.63-4.74)) compared to sRT, and 3.1 times higher (HR 3.12 [95% CI, 1.91-5.10)) compared to hRT. The broad implementation of hRT into clinical practice is specific to all modern radiation oncology. This trend is currently underway due to the specific positive clinical effects of hRT, which are discussed in detail in our publication. Conclusions: Our study demonstrates comparable survival outcome between sRT and hRT groups. This is an argument in favor of the feasibility of using hRT as a part of multimodal GBM treatment in terms of oncological outcomes. Further studies are needed to identify specific stratification groups of GMB patients with the greatest survival and quality of life benefits due to hRT.
- 27 March 2023
- Published by Romodanov Neurosurgery Institute in Ukrainian Neurosurgical Journal
- Vol. 29 (1) , 38-47
Open AccessHypofractionated radiotherapy of patients with glioblastoma: the first experience in Ukraine and prospects view
Objective: To assess the survival of patients (pts) with newly diagnosed glioblastoma (GBM) in groups with hypofractionated regime radiotherapy, standard fractionationated regime radiotherapy and whole brain irradiation. Materials and methods: A retrospective non-randomized single-center study of 205 pts with GBM grade 4 according to the WHO classification treated in Romodanov Neurosurgery Institute named after Acad. A.P. Romodanov National Academy of Medical Science of Ukraine (2014–2020). The mean age of pts 53.8 years (95% CI 52.1 - 55.5); there were 114 men (55.6%) and 91 women (44.4%). According to the regimen radiotherapy (RT), pts were divided into 3 groups: 49 (23.9%) pts (standard RT: 2.0 Gy per fraction in 30 fractions, total dose 60.0 Gy) – group "sRT", 110 (53.7%) pts (hypofractionated RT: 3.5 Gy per fraction in 15 fractions, total dose 52, 5 Gy) - group "hRT", 46 (22.4%) pts – group "WBRT" (whole brain radiation). Differences in progression-free survival (PFS) and overall survival (OS) between the three groups were analyzed using Kaplan–Meier survival curve, log-rank test and Pearson Chi-square test. Results: The median OS is 15,0 (95% CI 14,1 – 17,1), 16,5 (95% CI 14,1 – 18,8) and 8,7 (95% CІ 7,5 – 9,5) months for sRT, hRT and WBRT, respectively. There is a significant difference in OS for sRT and hRT compared to WBRT (p=0.00000), without difference in OS between sRT and hRT (p=0.06757). The median PFS in sRT and hRT does not differ significantly: sRT – 9.0 (95% CI 9.0 - 10.0) months; hRT – 9.0 (95% CI 8.0 - 10.0) months. The median OS for WBRT is 5.1 (95% CI 4.0 - 6.0) months. There is a significant difference in PFS for sRT and hRT compared to the WBRT (p=0.00000), without difference in PFS between sRT and hRT (p=0.43374). The risk of death for WBRT compared to sRT is 2.5 times higher (HR 2.5 [95% CI, 1.45 - 4.46)) and 3.5 times higher compared to the hRT group (HR 3.5 [95% CI, 2.09-5.88)). The risk of progression for WBRT is 2.8 times higher (HR 2.78 [95% CI, 1.63-4.74)) compared to sRT, and 3.1 times higher (HR 3.12 [95% CI, 1.91-5.10)) compared to hRT. The broad implementation of hRT into clinical practice is specific to all modern radiation oncology. This trend is currently underway due to the specific positive clinical effects of hRT, which are discussed in detail in our publication. Conclusions: Our study demonstrates comparable survival outcome between sRT and hRT groups. This is an argument in favor of the feasibility of using hRT as a part of multimodal GBM treatment in terms of oncological outcomes. Further studies are needed to identify specific stratification groups of GMB patients with the greatest survival and quality of life benefits due to hRT.
- Open Access
- 27 March 2022
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 128 (1) , 57-73
Survival after stereotactic radiosurgery of recurrent glioblastomas in patients with radical resection of primary tumor
гліобластома (ГБ) – це агресивна пухлина, що характеризується високим рівнем рецидивування та призводить до смерті більшості хворих через 15–18 місяців після встановлення діагнозу. Факторами, що асоціюються з більш тривалою виживаністю хворих на ГБ, є вік до 50 років, кращий функціональний статус та радикальна резекція первинної пухлини. Оптимальне лікування при рецидиві або прогресуванні ГБ до цього часу не визначено та залишається складною проблемою. Стереотаксична радіохірургія (СРХ) є методом прецизійного високотехнологічного опромінення, що розглядається сьогодні як терапевтична опція ефективного впливу на рецидивні злоякісні гліоми. Метою даного ретроспективного дослідження був аналіз виживаності після СРХ рецидивної ГБ в когорті 59 хворих, яким було проведено радикальну резекцію первинної пухлини. Досліджувана когорта складалась з 59 хворих (28 / 47,5% жінок та 31 / 52,5% чоловіків); середній вік в загальній групі склав 51 рік (інтервал 24 – 81). СРХ проводилось на лінійному прискорювачі «Trilogy» (США) (6 MeV) в період з 2014 р. по 2020 р. в Державній установі «Інститут нейрохірургії ім. акад. А.П. Ромоданова НАМН України». В усіх випадках діагноз ГБ 4 ступеню за класифікацією ВООЗ був підтверджений патоморфологічно після резекції первинної пухлини. Всім 59 хворим було проведено максимальне безпечне видалення первинної пухлини в радикальному об’ємі: в переважній кількості спостережень (54 / 91,5%) – по перифокальній зоні; в 5 / 8,5% випадках – субтотально. В усіх 59 випадках хворим було проведено ад’ювантне променеве лікування після видалення первинної пухлини (сумарна вогнищева доза (СВД) 60 Гр, 30 фракцій), яке в 33 випадках було поєднане з алкілюючою ХТ (темозоломід 75 мг/м2). У 31 / 52,5 % хворого після завершення конкомітантної ХТ продовжилось ХТ лікування (темозоломід 150-200 мг/ м2). У більшості спостережень (51 / 86,4 %) РГБ було діагностовано за сукупністю клініко-радіологічних ознак; у 8 / 13,6 % хворих – патоморфологічно, після повторного хірургічного втручання. Кінцевими точками дослідження були загальна виживаність (ЗВ), безрецидивна (безпрогресивна) виживаність (БРВ) та виживаність після настання рецидиву (ВПР). Вивчався вплив на виживаність наступних кількісних та категоріальних факторів: стать, вік, функціональний статус, поєднання ад’ювантної ПТ з алкілюючою ХТ, хірургічне видалення РГБ, тип рецидивування ГБ, дозове навантаження за всі курси опромінення сумарно (за біологічно-ефективною дозою (BED11)) та при СРХ, кількість фракцій СРХ, об’єм мішені СРХ, термін безрецидивного періоду/виживаності (БРВ). Вплив на виживаність такого фактору як БРВ досліджувався шляхом розподілення когорти на три незалежні групи в залежності від тривалості безрецидивного періоду: група I – БРВ < 10 місяців; група II – БРВ від 10 до 20 місяців; група III – БРВ > 20 місяців. Виживаність хворих була проаналізована методом Каплана-Майера (КМ). Логарифмічний ранговий тест (для порівняння КМ кривих виживаності для різних досліджуваних груп) використовували для дослідження виживаності за бінарними предикторами. Порівняння впливу декількох категоріальних факторів на виживаність здійснювалось за допомогою χ2-тесту (Pearson Chi-square test). Для дослідження впливу на виживаність кількісних коваріат використовували регресійний аналіз за моделлю пропорційних ризиків...
- 27 March 2022
- Published by Bogomolets National Medical University in Ukrainian Scientific Medical Youth Journal
- Vol. 128 (1) , 57-73
Open AccessSurvival after stereotactic radiosurgery of recurrent glioblastomas in patients with radical resection of primary tumor
гліобластома (ГБ) – це агресивна пухлина, що характеризується високим рівнем рецидивування та призводить до смерті більшості хворих через 15–18 місяців після встановлення діагнозу. Факторами, що асоціюються з більш тривалою виживаністю хворих на ГБ, є вік до 50 років, кращий функціональний статус та радикальна резекція первинної пухлини. Оптимальне лікування при рецидиві або прогресуванні ГБ до цього часу не визначено та залишається складною проблемою. Стереотаксична радіохірургія (СРХ) є методом прецизійного високотехнологічного опромінення, що розглядається сьогодні як терапевтична опція ефективного впливу на рецидивні злоякісні гліоми. Метою даного ретроспективного дослідження був аналіз виживаності після СРХ рецидивної ГБ в когорті 59 хворих, яким було проведено радикальну резекцію первинної пухлини. Досліджувана когорта складалась з 59 хворих (28 / 47,5% жінок та 31 / 52,5% чоловіків); середній вік в загальній групі склав 51 рік (інтервал 24 – 81). СРХ проводилось на лінійному прискорювачі «Trilogy» (США) (6 MeV) в період з 2014 р. по 2020 р. в Державній установі «Інститут нейрохірургії ім. акад. А.П. Ромоданова НАМН України». В усіх випадках діагноз ГБ 4 ступеню за класифікацією ВООЗ був підтверджений патоморфологічно після резекції первинної пухлини. Всім 59 хворим було проведено максимальне безпечне видалення первинної пухлини в радикальному об’ємі: в переважній кількості спостережень (54 / 91,5%) – по перифокальній зоні; в 5 / 8,5% випадках – субтотально. В усіх 59 випадках хворим було проведено ад’ювантне променеве лікування після видалення первинної пухлини (сумарна вогнищева доза (СВД) 60 Гр, 30 фракцій), яке в 33 випадках було поєднане з алкілюючою ХТ (темозоломід 75 мг/м2). У 31 / 52,5 % хворого після завершення конкомітантної ХТ продовжилось ХТ лікування (темозоломід 150-200 мг/ м2). У більшості спостережень (51 / 86,4 %) РГБ було діагностовано за сукупністю клініко-радіологічних ознак; у 8 / 13,6 % хворих – патоморфологічно, після повторного хірургічного втручання. Кінцевими точками дослідження були загальна виживаність (ЗВ), безрецидивна (безпрогресивна) виживаність (БРВ) та виживаність після настання рецидиву (ВПР). Вивчався вплив на виживаність наступних кількісних та категоріальних факторів: стать, вік, функціональний статус, поєднання ад’ювантної ПТ з алкілюючою ХТ, хірургічне видалення РГБ, тип рецидивування ГБ, дозове навантаження за всі курси опромінення сумарно (за біологічно-ефективною дозою (BED11)) та при СРХ, кількість фракцій СРХ, об’єм мішені СРХ, термін безрецидивного періоду/виживаності (БРВ). Вплив на виживаність такого фактору як БРВ досліджувався шляхом розподілення когорти на три незалежні групи в залежності від тривалості безрецидивного періоду: група I – БРВ < 10 місяців; група II – БРВ від 10 до 20 місяців; група III – БРВ > 20 місяців. Виживаність хворих була проаналізована методом Каплана-Майера (КМ). Логарифмічний ранговий тест (для порівняння КМ кривих виживаності для різних досліджуваних груп) використовували для дослідження виживаності за бінарними предикторами. Порівняння впливу декількох категоріальних факторів на виживаність здійснювалось за допомогою χ2-тесту (Pearson Chi-square test). Для дослідження впливу на виживаність кількісних коваріат використовували регресійний аналіз за моделлю пропорційних ризиків...